Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.

about

Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.

P2860

Q41548612-8AC9EC54-4B97-4AAD-83A0-9E51479AEC07

P2860

Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.

Item

http://www.wikidata.org/entity/Q38778205

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Anti-bevacizumab idiotype anti ...... se, impairing tumor outgrowth.

@en

type

Item

label

Anti-bevacizumab idiotype anti ...... se, impairing tumor outgrowth.

@en

prefLabel

Anti-bevacizumab idiotype anti ...... se, impairing tumor outgrowth.

@en

P1476

Anti-bevacizumab idiotype anti ...... se, impairing tumor outgrowth.

@en

P2093

Carolina Bellini Parise

http://www.w3.org/2001/XMLSchema#string

Jane Zveiter de Moraes

http://www.w3.org/2001/XMLSchema#string

Juliana Mayumi Suzuki

http://www.w3.org/2001/XMLSchema#string

Jéssica de Souza Sanches

http://www.w3.org/2001/XMLSchema#string

Roger Chammas

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Angiogenesis in cancer and other diseases

Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.

P304

551-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12903

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Rodrigo B Aguiar

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27079440

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

bevacizumab

P932

4832859

http://www.w3.org/2001/XMLSchema#string

Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.

about

P2860

P2860

Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932